Thermo Fisher Scientific Inc
I · KI-Analyse
Kurzfassung
Thermo Fisher supplies the tools, chemicals, and services that pharmaceutical companies and research labs need to discover drugs, manufacture medicines, and run diagnostic tests. They operate across four segments: Life Sciences Solutions (research reagents and instruments), Analytical Instruments (lab equipment), Specialty Diagnostics (clinical testing products), and Laboratory Products and Biopharma Services (contract manufacturing and research services for drug companies).
Thermo Fisher Scientific is a $166.4 billion life sciences and laboratory equipment company that provides instruments, reagents, diagnostics, and contract manufacturing services to pharmaceutical, biotech, and research customers worldwide [Yahoo Finance]. The company serves as a critical infrastructure provider for drug development, with recent growth driven by expanding bioprocess services, new laboratory facilities in Sweden, and partnerships to manufacture oncology drugs [Yahoo Finance]. Despite solid fundamentals, the stock has significantly underperformed the market over the past year, rising only 8.3% compared to the S&P 500's 25.2% gain [Yahoo Finance].
Thermo Fisher shows solid profitability with moderate leverage, though return on capital and stock performance lag expectations.
Sentinellis-Score
6.8/10
Moderate concerns
Marktkapitalisierung
$166.4B
Umsatz (12 Monate)
$44.6B
II · Aktuelle Nachrichten
Was den Kurs bewegt hat
6 stories · ranked by relevance
- macro2026-05-20
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
Yahoo Finance
- macro2026-05-19
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
Yahoo Finance
- macro2026-05-18
Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading
Yahoo Finance
- macro2026-05-18
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps
Simply Wall St
- macro2026-05-18
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
Yahoo Finance
- macro2026-05-18
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone
Simply Wall St
Premium · kostenlos mit jedem Konto
The stock has badly underperformed the market, gaining only 8.3% over the past year while the S&P 500 rose 25.2%, and is down 24.4% year-to-date versus an 8.1% market gain [Yahoo Finance]. This persistent weakness suggests investor concerns about growth trajectory or valuation.
Risiken
4
Chancen
5
Warnsignale
1
Führung
10
19 weitere Erkenntnisse im vollständigen Bericht — kostenlos mit jedem Konto.
Vollständige Thermo Fisher Scientific Inc-Analyse freischalten
Erstellen Sie ein kostenloses Konto für den vollständigen KI-Bericht mit Quellenangaben im Text.
- 4 Risiken, 5 Chancen und 1 Warnsignal — jeweils mit Quelle
- Über 100 Finanzkennzahlen mit Charts und Vergleichen
- Vollständige Nachrichten-Zusammenfassungen mit Quellenlinks
- Führungsteam und Vergütung
- PDF-Export für offline
III · Ähnliche Unternehmen
Das könnte Sie auch interessieren
Same sector · Healthcare or comparable health
Auf Ihre Watchlist setzen?